Navigation Links
Yongye International Announces First Quarter 2013 Financial Results
Date:5/10/2013

BEIJING, May 10, 2013 /PRNewswire-FirstCall/ -- Yongye International, Inc. (NASDAQ: YONG), ("Yongye" or the "Company") a leading developer, manufacturer, and distributor of crop nutrient products in the People's Republic of China ("PRC"), today announced its financial results for the quarter ended March 31, 2013.

First Quarter 2013 Financial Highlights

  • Revenue decreased 29.7% to $45.3 million from $64.4 million in the first quarter of 2012
  • Shipments of Yongye's agricultural nutrient products decreased 37.3% to $43.7 million in the first quarter of 2013 from $69.6 million in the first quarter of 2012
  • Gross profit decreased 38.9% year-over-year to $21.6 million
  • Income from operations was $1.1 million, compared to $21.9 million in the first quarter of 2012
  • Net loss attributable to Yongye was $0.6 million, or a loss of $0.03 per diluted share, from net income of $16.4 million, or income of $0.27 per diluted share, in the same period of 2012  
  • Adjusted net income attributable to Yongye, which excludes non-cash expenses related to the amortization of the acquired Hebei customer list, share-based compensation for management and independent directors, and a change in the fair value of derivative liabilities, was $0.1 million, or a loss of $0.01 per diluted share, compared to an adjusted net income attributable to Yongye of $18.3 million, or $0.31 per diluted share, in the same period of 2012*
  • The Company collected $226 million from its distributors during the first quarter of 2013
  • Operating cash flow was $141.1 million compared to $61.7 million in the same period of 2012
  • Mr. Zishen Wu, Chairman and Chief Executive Officer of Yongye International, stated, "During the first quarter of 2013, we focused our efforts on the collection of overdue account receivables. To better manage our accounts re
    '/>"/>

    SOURCE Yongye International, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Yongye International to Report First Quarter 2013 Financial Results on May 10, 2013
    2. Yongye International Announces Second Quarter 2012 Financial Results
    3. Yongye International to Report Second Quarter 2012 Financial Results on August 9, 2012
    4. Dr. Szczepan Baran will be Presenting at the International Microsurgical Simulation Society at Columbia University in New York
    5. Dyadic International To Announce First Quarter 2013 Financial Results And Host Conference Call On Wednesday, May 15, 2013
    6. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
    7. Lisa Lorraine Reyes Muñoz, GeneCell International’s Physician Relation's Manager Launches Educational Meetings for General Public on Umbilical Cord Blood Stem Cells
    8. Danai Brooks Joins Dyadic International as Chief Operating Officer
    9. PAREXEL International Announces Acquisition of HERON Group LTD, A Leading Commercialization Consultancy
    10. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
    11. GeneCell International Gives Back to the Community by Participating in Local Elementary School’s Career Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
    (Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
    (Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
    Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
    ... Inc. (Nasdaq: MYL ) today announced ... Biocon Limited, a publicly traded company on the ... the development, manufacturing, supply and commercialization of multiple, ... marketplace. Through this partnership, Mylan and Biocon bring ...
    ... June 29 , - Financing ... Gyros AB, the leading provider of ... SEK 80 million,(approximately euro 7.5 million) in an equity fundraising ... will enable Gyros to drive,the further commercialization of its Gyrolab ...
    ... , MENLO PARK, Calif., June 29 Kornberg Associates | ... Stanford University to design a new Cognitive & ... the announcement. The firm has worked with Stanford ... the past 30 years, one of which is the two-story, ...
    Cached Biology Technology:Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 2Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 3Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market 4Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals 4Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2
    (Date:7/11/2014)... South Wales, Australia when NASA,s Aqua satellite passed overhead ... 11 (12:35 p.m. local time/11:35 p.m. EDT on July ... (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard captured ... smoke (light brown) from various fires. Actively burning areas, ... , The New South Wales, Australia Government website "NSW ...
    (Date:7/11/2014)... release is available in German . ... a method that uses the refraction of X-rays through ... images produced with this method are often of much ... in the team of Prof. Franz Pfeiffer are particularly ... and therapy including X-ray phase-contrast imaging. One main ...
    (Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
    Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
    ... may have just gotten a little louder. Researchers ... genes under control of in living things than suspected only ... model organism is dramatically higher than previously reported. The new ... "This new finding may help to explain why ...
    ... blasts in Hiroshima and Nagasaki, Japan, in 1945, likely ... thyroid cancer as adults, according to Japanese researchers. ... Research , a journal of the American Association for ... close to the blast sites, were comparably young at ...
    ... Researchers report the discovery of the first new living species ... to be published online on August 28th in Current ... that the new species, called Tridacna costata , once ... the Red Sea, it now represents less than one percent ...
    Cached Biology News:Study shows more genes are controlled by biological clocks 2Study shows more genes are controlled by biological clocks 3Researchers discover atomic bomb effect results in adult-onset thyroid cancer 2New giant clam species offers window into human past 2
    ... system uses a burst of high-pressure ... acid-coated gold or tungsten microparticles to ... or organelles without dependence or interaction ... includes helium pressure regulator, solenoid, spacer ...
    ... system, 220-240 V, is used for ... The system includes the BioLogic LP ... MV-6 injection valve, proportioning valve or ... and fittings kit, column and conductivity ...
    Sf21 Insect Cells (Frozen) in Max-XP Medium...
    ... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
    Biology Products: